EAHP represents over 29,000 hospital pharmacists across 36 member countries. EAHP represents and develops the hospital pharmacy profession within Europe in order to ensure the continuous improvement of care and outcomes for patients in the hospital setting. This is achieved through science, research, education, practice, as well as sharing best-practice and responsibility with other healthcare professionals.
The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
The EAHP staff supports the Board in executing EAHP’s mission. The Staff assists in financial management, events organisations, policy activities and all EAHP projects. The EAHP staff works closely with EAHP’s members and ensures the effective communication all relevant stakeholders.
The first member countries were Belgium, Britain, Denmark, France, the Federal Republic of Germany and The Netherlands in 1972. EAHP has now 36 EAHP members and 2 Associate Members. EAHP is open to countries members of the Council of Europe and since 2022 to organisations representing the interests of hospital pharmacists from outside the Council of Europe (Associate Membership)
EAHP’s structure is also composed by different standing committes: EAHP Scientific Committee, EAHP Education Executive Committee and the EAHP CTF Steering Committee.
At EAHP, we are committed to transparency in our governance, ethical standards, and funding practices. This section provides open access to our foundational documents, including the EAHP Statutes, Code of Conduct, and Funding Sources. By sharing these resources, we aim to uphold accountability and foster trust with our members, partners, and the public.
Keep up with all EAHP’s events and webinars. Contact the team at info@eahp.eu should you have any questions about upcoming events or activities.
Here you can find all upcoming events organised by EAHP and by all its members and associate members. Do not hesitate to contact the events team at events@eahp.eu should you have any questions about the organisation of these events.
Hospital pharmacists conduct a critical role in the care of patients in hospitals. Learn more about what they do here and in all the pages under Hospital Pharmacy practice and Policy.
Self-Assessment
SILCC
Closed SIGs
EAHP brings together experts from many areas of hospital pharmacy practice providing and highlighting good local sustainable practices as that can be up-scaled and shared with other countries. The EAHP Working Group on Sustainability has the aim of reducing the environmental burden of the hospital pharmacy services.
The European Association of Hospital Pharmacists (EAHP), and its 36 member country platforms are creating a Common Training Framework for the hospital pharmacy education in Europe. The goal of this project is to allow the free movement of hospital pharmacists within the European Union.
The European Association of Hospital Pharmacists (EAHP) and the European Society of Clinical Pharmacy (ESCP) have collaboratively developed the Oath to Society. The Oath to Society is all encompassing and acts as a contract for excellence in providing compassionate patient care, working as part of the healthcare team and advancing the pharmacy profession, and showcasing how clinical and hospital pharmacists work every day
A day created to highlight the importance and to celebrate the work done by hospital pharmacies. This day celebrates all hospital pharmacy teams.
Catch up with EAHP’s press releases
Find all EAHP relevant publication like the EAHP Surveys, annual reports and the history books.
The European Journal of Hospital Pharmacy (EJHP) is the only official journal of the European Association of Hospital Pharmacists (EAHP) and is committed to advancing the science, practice and profession of hospital pharmacy. As the premier communication platform for hospital pharmacists worldwide, EJHP is a major source for continuing education as well as updates on advances in the practice and standard of pharmaceutical care for patients.
When EAHP and Hospital pharmacists appear in the news.
EAHP publishes a monthly EU monitor with updates about the latest EAHP initiatives and information relevant for the hospital pharmacy profession.
Sponsor Channel
The Sponsor Channel is designed to maximise visibility and engagement, allowing sponsors to connect with the hospital pharmacy community and partners in a dynamic and interactive environment. From product demonstrations to networking sessions, the Sponsor Channel offers a range of opportunities for sponsors to showcase their offerings and generate leads in the new EAHP Website.
The EAHP EU Monitor is a regular round up of news relevant to hospital pharmacy in Europe.
EAHP has introduced a new and exciting concept to keep you updated with our latest projects and initiatives: the Catch up with EAHP Webinar. Make the most of our resources and learn about our latest projects, initiatives and ways of collaboration. Whether you are already very familiar with EAHP or a newcomer, this webinar is for everyone. It will take place on the 14th of December at 6.00 PM CET on the online platform ZOOM.
Register in advance for this meeting HERE.
The crises of the recent years have concretely highlighted the key role of pharmacists in health crisis management. This experience also underlined the value of preparedness to respond to such situations. In this context, the Specialised Centre for Emergency and Disaster Pharmacy opens the registration for its third edition of the CAS “Medicines and medical devices in emergency and disaster situations”, starting at the end of January 2024. The objective of this CAS is to provide a recognised interprofessional post-graduate university training in emergency and disaster pharmacy. Indeed, in crisis contexts, including humanitarian crises and daily emergencies in (pre-)hospital and hospital settings, the role of drugs and medical devices is obvious in treating victims and guaranteeing the survival of most individuals. In this respect, specific pharmaceutical and pharmacological knowledge is essential for every health professional involved in emergency and disaster situations.
This program provides qualified pharmacists, physicians, paramedics and other health professionals with new skills and/or updated knowledge, thus strengthening their expertise in this specific field. Courses are taught mainly in English and international participants are welcome. They consist of 6 thematic modules of 2-3 days each and a small final thesis. They will be organized in the Geneva, Lausanne and Bern areas in Switzerland. The registration deadline for the entire CAS is 30 November 2023 (but can be extended on request). The modules are also be offered on an individual basis.
Learn more about the CAS on “Medicines and medical devices in emergency and disaster situations” HERE.
EHMA and EAHP are conducting a survey targeting hospital pharmacists and pharmacy managers, focusing on the collection and sharing of data related to medication demand and stocks. The survey aims to identify how hospitals currently gather and share data on medication stock and demand, identify any barriers to collecting information on medicines stocks, and explore the workload implications and digitalisation requirements for hospital pharmacy workflows in relation to data collection. The survey will remain open for three months. The results will be collected and published in a briefing paper that will be shared with EU policymakers and the European Medicines Agency.
Find the survey HERE.
In light of the Antimicrobial Awareness Week, ECDC released the Annual Epidemiological Report about Antimicrobial Antimicrobial Consumption in the EU/EEA for 2022. The total consumption of antibacterials for systemic use has decreased by 2.5% since 2019, indicating slow progress towards the EU target reduction of 20% by 2030. In the hospital sector, the EU/EEA mean consumption of antibacterials for systemic use (ATC group J01) was 1.61 DDD per 1,000 inhabitants per day (country range: 0.75 (Netherlands) –3.15 (Czechia). During 2013–2022, a statistically significant decrease was observed at the EU/EEA level. However, the EU/EEA hospital sector has also seen a rise in the percentage of AMC from the ‘Reserve’ group (i.e. antibiotics for the treatment of confirmed or suspected infections due to multidrug-resistant organisms). Among 21 countries for which 10-year trend analyses were performed, 17 (81%) countries had increasing trends in the percentage of hospital AMC from the ‘Reserve’ group of antibiotics. Not one EU/EEA country has a decreasing trend in the percentage of ‘Reserve’ group AMC in the hospital sector.
Learn more about it HERE.
The Heads of Medicines Agencies (HMA), the European Commission (EC) and the European Medicine Agency have published the first electronic product information (ePI) for a selection of human medicines. They are part of a pilot that aims to improve accessibility for healthcare professionals and patients by transitioning from traditional PDF documents to real-time, electronically accessible information. The one-year pilot involves 25 medicines from Denmark, the Netherlands, Spain, and Sweden and is testing the integration of ePIs into regulatory procedures. The project is expected to finish in July 2024, and depending on the outcomes, it will inform us to integrate the ePIs into common practice and expand their use across the EU.
The ePI’s for the selected medicines within the project can be found HERE.
On the 13th of December 2013, from 9.00 to 16.30, the European Commission organised the 7th Biosimilar Multistakeholder Event in Brussels (it is also possible to attend the event online). The event will discuss several topics related to the development and use of biosimilars: How to address the challenges and lack of biosimilar competition in certain areas of the biologic pipeline, Disparities in biosimilar uptake and access (across EU Member States within countries and regions), Consequences of product formulation and administration for patients, healthcare professionals and systems (both in terms of opportunities and challenges).
Learn more about it HERE.
The European Commission is looking for six independent scientific experts for EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) for a three-year mandate starting on 2 July 2024. The deadline for submission of applications is on the 7th of December before 12:00 CET.
Find more information HERE.
Medication adherence is essential to collect reliable outcomes in clinical trials. A recent article published in the European Journal of Hospital Pharmacy (EJHP) aimed to assess how and to what extent medication adherence is reported in pivotal clinical trials of oral cancer drugs. 56 clinical trials concerning 30 oral cancer drugs authorised by the European Medicines Agency were analysed. Eleven articles (19.6%) contained a mention of medication adherence in the main document, 26 (46.4%) in the supplementary material, and 19 (33.9%) did not contain any reference to adherence. Seven studies reported medication adherence between the results, expressed as the number of patients discontinuing treatment for non-compliance and mean or median percentage. It can, therefore, be concluded that medication adherence in pivotal clinical trials of oral oncological drugs is poorly represented. A greater level of reporting in the results is needed and should be included among the minimum set of recommendations in reporting health research.
Read the article HERE.
EMA launched a concept paper on the development of an addendum to the Guideline on Clinical Development of Vaccines on clinical trials for vaccines for immunocompromised individuals. The Guideline on clinical evaluation of vaccines EMEA/CHMP/VWP/164653/05 Rev. 1 (3) does not provide detailed guidance on the design of clinical trials to assess the safety, immunogenicity and efficacy of vaccines in immunocompromised individuals. There is a need to provide some guidance on potentially suitable sub-populations of immunocompromised individuals for trials to improve the extrapolation of the findings to other sub-populations. Moreover, there is a need to consider designing studies in immunocompromised individuals that also indicate alternative doses and/or regimens that could provide adequate levels of protection against infectious diseases. All interested parties are invited to comment on the concept paper. The public consultation is open until 1 January 2024.
Contribute HERE
EMA published the draft of the 3rd revision of the Guideline on clinical investigation of medicinal products in the treatment of epileptic disorders. The public consultation is open until the 1st of January 2024.
Contribute HERE
The Guideline on the clinical requirements for non-replacement therapy in haemophilia A and B describes the main clinical data needed to support an application for a marketing authorisation for non-replacement therapy for use in the prevention of bleeding in patients with haemophilia A and/or haemophilia B. The public consultation is open until the 1st of January.
Contribute HERE
The current influenza vaccines guideline covering non-clinical and clinical modules (EMA/CHMP/VWP/457259/2014) was adopted in July 2016. Developments in the field of influenza vaccines and experience with applications for scientific advice and marketing authorisation since 2016 have pointed to the need for additions to and revisions of the current text. The proposed guideline will replace the Guideline on influenza vaccines and non-clinical and clinical modules (EMA/CHMP/VWP/457259/2014). The public consultation is open until the 1st of January 2024.
Contribute HERE
The Health Emergency Preparedness and Response Authority (HERA) was set up by the Commission in 2021 to respond to the COVID-19 pandemic. The Commission has opened up a public consultation to gather views from a broad range of stakeholders on the performance and wider impacts of HERA. This consultation will assess whether HERA effectively and efficiently contributed to the political objective of strengthening the EU’s health emergency preparedness and response and fulfilling its assigned tasks. Furthermore, the aim is to look at the complementarity with work carried out by other EU bodies, the extent to which HERA’s mandate fits the current health challenges and if any changes to this mandate are needed. The public consultation is open until the 19th of February 2024.
Contribute HERE
